Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05369494 · ClinicalTrials.gov registry record · NA
Infants Fed a Hydrolyzed Infant Formula
A NA study, sponsored by Abbott Nutrition.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
NCT05369494: Completed NA study, sponsored by Abbott Nutrition.
NCT05369494 is a NA study that has completed, run by Abbott Nutrition. The registered enrollment target is 33 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05369494, a NA study, has completed, sponsored by Abbott Nutrition.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this non-randomized, multi-center study is to evaluate the growth, tolerance and compliance of an extensively hydrolyzed infant formula in an intended use population of infants.
Primary Outcome
Change in weight for age z-score
Interventions
- OTHER Hydrolyzed protein infant formula with oligosaccharides
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2022-05-07 |
| Est. Completion | 2023-11-18 |
| Phase | NA |
What the finished NCT05369494 record still lists
NCT05369494 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Hydrolyzed protein infant formula with oligosaccharides is the first listed.
NCT05369494 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05369494 about?
NCT05369494 is a clinical study titled "Infants Fed a Hydrolyzed Infant Formula". The purpose of this non-randomized, multi-center study is to evaluate the growth, tolerance and compliance of an extensively hydrolyzed infant formula in an intended use population of infants.
What is the current status of trial NCT05369494?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2022-05-07. Estimated completion is 2023-11-18.
What interventions are being tested in trial NCT05369494?
The interventions under investigation include: Hydrolyzed protein infant formula with oligosaccharides (OTHER).
Who is sponsoring clinical trial NCT05369494?
This trial is sponsored by Abbott Nutrition, which has 89 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05369494's enrollment target sits among peer trials
33 1574th of 2000 higher than 423 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI